| Bioactivity | SCH 336 is a potent, selective, inverse and orally active CB2 agonist. SCH 336 inhibits BaF3/CB2 migration. SCH 336 significantly inhibits the migration of leukocytes in vivo. SCH 336 blocks ovalbumin-induced lung eosinophilia in mice[1]. |
| Invitro | SCH 336 (Sch.336) (0-10 µM) competes with [3H]CP55,940 for binding to human CB2 on Sf9 cell membranes with Ki of 1.8 nM, and decreases GTPγS binding on human CB2-containing membranes with an EC50 of 2 nM, decreases potency on CB1-containing membranes with EC50 of 200 nM[1].SCH 336 inhibits BaF3/CB2 migration to 100 nM 2-AG with an IC50 of 34 nM[1]. |
| In Vivo | SCH 336 (0.02, 0.2, 2.0 mg/kg; i.p.) significantly inhibits the migration of leukocytes[1]. Animal Model: |
| Name | SCH 336 |
| CAS | 447459-51-0 |
| Formula | C23H25NO8S3 |
| Molar Mass | 539.64 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Lunn CA, et al. A novel cannabinoid peripheral cannabinoid receptor-selective inverse agonist blocks leukocyte recruitment in vivo. J Pharmacol Exp Ther. 2006 Feb;316(2):780-8. |